HSBC analyst Rajesh Kumar lowered the firm’s price target on Novo Nordisk (NVO) to $102 from $160 and keeps a Buy rating on the shares. The firm says the confluence of first-time U.S. tariffs risks combined with a large patent cliff and Part D/Inflation Reduction Act headwinds might create some pressure on biopharma earnings. HSBC’s analysis suggests innovative pharma could face earnings headwinds of roughly 6%-14% if a 25% U.S. tariff were applied. A closer scrutiny of accounts and supply chains reveals potential risks to earnings might stem from other mechanisms such as tax rates, depending on how tariffs are structured, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk downgraded to Sell from Buy at DBS Bank
- Novo Nordisk downgraded to Market Perform from Outperform at BMO Capital
- ‘Time to Make a Warren Buffett Move,’ Says Top Investor About Novo Nordisk Stock
- Eli Lilly Stock (LLY) Back in Shape as It Sues Compounders Over Weight-Loss Drugs
- Hims & Hers Stock (HIMS) Dips After FDA Flags Safety Concerns
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue